Skip to main content

Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia.

Cell2026-05-08PubMed
Total: 90.0Innovation: 10Impact: 0Rigor: 0Citation: 0

Summary

Two distinct clades of SARS-CoV-2–related coronaviruses co-circulate in Thai horseshoe bats. One clade binds human ACE2 yet shows reduced fusogenicity, replication, pathogenicity, and transmissibility versus SARS-CoV-2. Recombination and recent geographic movement shape their complex evolutionary dynamics, informing risk assessment and surveillance.

Key Findings

  • Identified two SC2r-CoV clades co-circulating in the same bat population in Thailand.
  • One clade binds human ACE2 but shows reduced fusogenicity, replication, pathogenicity, and transmissibility compared with SARS-CoV-2.
  • Phylogeography and recombination analyses reveal extensive recent geographic movement and inter-lineage recombination shaping evolution.

Clinical Implications

Refines priority targets for genomic surveillance, helps calibrate spillover risk, and guides preemptive countermeasure development (e.g., broadly neutralizing antibodies, vaccines) against high-risk sarbecoviruses.

Why It Matters

This study integrates structural, in vitro, in vivo, and phylogeographic analyses to functionally de-risk bat coronaviruses with human ACE2-binding capacity, providing an evidence-based framework for surveillance and pandemic preparedness.

Limitations

  • Findings derive from bat sampling in Thailand; generalizability to other regions and hosts remains uncertain.
  • Reduced in vitro/in vivo fitness versus SARS-CoV-2 does not eliminate future adaptation potential.

Future Directions

Expand longitudinal, multi-country bat and intermediate-host surveillance with functional characterization; assess cross-neutralization by broadly neutralizing antibodies and pan-sarbecovirus vaccine candidates.

Study Information

Study Type
Case series
Research Domain
Pathophysiology
Evidence Level
IV - Preclinical mechanistic and in vivo evidence without direct clinical outcomes.
Study Design
OTHER